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Abstract 
BACKGROUND: Drug-induced melanoma is a topic, concept or "reality" becoming more and more popular as the 
list of drugs considered as potential inducers of cutaneous melanoma is constantly growing. Interesting and 
current at the moment is the question/dilemma of "Irbesartan induced melanomas" and "Valsartan induced 
melanomas"! The following questions are without answers: 1) the general risk which angiotensin receptor 
blockers contain for potentiating the carcinogenesis and cancer development (as a whole);  2) available 
officialized data for withdrawal from the market of products with valsartan and irbesartan due to detected potential 
carcinogens-NDMA/NDEA, and 3) the missing official information on the most likely forms of cancer potentiated 
by these drugs. That is precisely why many questions remain open, and the inevitable assumption arises for the 
key, although according to some conspiratorial role of so-called "pharmaceutical giants" in the concept of drug-
induced malignancies. 
CASE REPORT: We present a 72-year-old man with arterial hypertension in connection with which he is taking 
Irbesartan 300 mg (1-0-0), Amlodipine 5 mg (0-0-1) and Moxonidine 0.2 mg (0-0-1). The patient reported the 
presence of pigment lesion in the head area, which dates from many years and 3 years ago it was at the size of 
the nail plate on the index finger. Irbesartan therapy dates from 1.5-2 years, and according to the patient 1.5-2 
years after the start of irbesartan therapy, the lesion grew sixfold, accompanied by sensitivity and discomfort in 
the area. Clinically and dermatoscopically the lesion had data on superficial spreading cutaneous melanoma. 
Tumour thickness ≤ 1 mm was measured preoperatively by ultrasound. The so-called one-step melanoma surgery 
(OSMS) was performed, and the lesion was removed by elliptical excision with an operative surgical margin of 1 
cm in all directions within one operative session. The subsequent histological study (and screening staging) found 
that it was a superficial spreading melanoma stage IA (T1bN0M0). 
CONCLUSION: Possible, but unlikely, in our opinion, is that the intake of angiotensin receptor blockers (in 
particular irbesartan), and the progression of benign precursor lesions to malignant do not have a direct 
relationship. The growing number of data in the literature for drug-induced melanoma and massive withdrawal of 
products with valsartan and irbesartan due to the content of probable carcinogens speaks, however in favour of 
the opposite, namely that it is more likely to speak about established dependence than of a sporadic association. 
Drug-induced melanoma-rather a reality than a myth. 
 
 
 
 
Introduction 
 
In September 2018, NEJM-Journal 
Watch/New England Journal of Medicine shared 
information for revealed content of two potential 
carcinogens-NDMA and NDEA in the drug valsartan 
[1], [2]. It can be said that spreading drugs containing 
one or more carcinogens... becomes modern [1], [2]. 
Or just a trend? Normal and should not impress us!? 
[1], [2], [3], [4], [5], [6], [7]. Interesting is also the fact 
that high-grade NEJMs formalise information for 
carcinogens in medications. However, it does not tell 
what type of cancer is observed at, during or after 
their use [1], [2]. We specifically refer to the group of 
angiotensin receptor blockers [1], [2].  
 
 
Case report 
 
We present a 72-year-old man with arterial 
hypertension controlled through medication with 
Irbesartan 300 mg (1-0-0), Amlodipine 5 mg (0-0-1) 
and Moxonidine 0.2 mg (0-0-1). The treatment with 
Irbesartan dates from 1.5-2 years. The patient was 
hospitalised for surgical removal of a pigment lesion in 
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the head area. According to the patient's data, the 
lesion dates from several years, and 3 years ago it 
was at the size of a nail plate on the index finger. One 
and a half to two years after the start of irbesartan 
therapy, the patient observed a sixfold increase in the 
size of the lesion, sensitivity and discomfort, which is 
the reason for his presentation at the hospital of the 
Ministry of Interior and the attendant surgical removal. 
During the dermatological examination in the area of 
regio parietalis dextra, a melanocytic formation with 
irregular shape, dark brown to black colour, uneven 
distribution of pigment and presence of regression 
zones, clinically and dermatoscopically suspected for 
superficial spreading melanoma was visualised 
(Figure a and b). Tumour thickness ≤ 1 mm was 
measured preoperatively by ultrasound. The so-called 
one-step melanoma surgery was performed, and the 
lesion was removed by elliptical excision with an 
operative safety margin of 1 cm in all directions within 
one operative session (Figure c and d). Due to the 
impossibility of closing the defect in its middle part, the 
decision was made to be performed advancement 
flap, and the skin flap was mobilised from the proximal 
part of the skull in the distal direction (Figure d). The 
wound edges were adapted and sewn with single 
interrupted sutures. The subsequent histological study 
found that it was a superficial spreading melanoma, 
Clark II level, Breslow's thickness of 1 mm, without 
ulceration. The staging was performed which 
established melanoma stage IA (T1bN0M0). The 
postoperatively established tumor thickness of 1 mm 
does not require re-excision, i.e. the required safety 
margin was respected within one surgical intervention. 
Due to this fact, the patient was left for clinical 
observation and a perfect cosmetic result was 
observed (Figure e). 
 
 
Figure 1: A), B) Clinical view of a melanocytic formation with irregular shape in the right parietal region, presence of regression zones, 
clinically and dermatoscopically suspected for melanoma; C) Elliptical excision of the lesion with 1 cm operational safety margin in all 
directions and performing of modificated advancement flap; D) Postoperative clinical status of surgical defect closed by single interrupted 
sutures; E) Clinical view of perfect cosmetic outcome 
 
Discussion 
 
The latest and newest literature data speak in 
favour of the concept that the definition of drug-
induced melanoma exists and becomes significance 
[8], [9], [10], [11] increasingly. Numerous data in the 
literature show that drugs for the treatment of 
schizophrenia and Parkinson's, for example, by 
various mechanisms affect melanogenesis and are 
capable of leading to a possible imbalance, ensuring 
respectively on the one hand 1) protection from 
melanoma development or 2) eventual progression to 
the last [11], [12], [13], [14], [15]. Interestingly, 
however, these are drugs for which there is no 
published or reported evidence of carcinogenic 
content [11], [12], [13], [14], [15]. But the latter are not 
stopped from production and application? 
Antihypertensive angiotensin receptor blockers are 
associated with an increased risk of not only 
melanomas development, but also other skin tumors 
[10]. With the case we presented, we ask two 
important questions: 1) are the so-called 
"pharmaceutical giants", with their produced and 
distributed drugs, in the root of potentiating 
carcinogenesis and the development of de novo 
malignant lesions? and 2) are, the so called 
"Pharmaceutical companies", able to distribute the 
same drugs that, within existing precursor formations 
(normal or dysplastic nevi), potentiate their 
progression to malignant? 
The mass withdrawal of products with 
valsartan and subsequently irbesartan (due to found 
content of potential carcinogens-NDMA and NDEA) by 
various drug companies, puts a number of "troubling 
questions", namely: First, "Based on what grounds or 
data companies have decided to check their products 
for carcinogens?" and secondly, "Do these" giants 
"have data for development or existing risk for the 
development of tumor formations (or already existing 
ones) within a possible reception of the indicated 
medications (currently unofficial)?" [1], [2], [3], [4], [5], 
[6], [7]. Only the answer to these questions can 
explain the rapid withdrawal of different products from 
different pharmaceutical companies. The rationale in 
the media and medical space at the moment for 
"potential carcinogenic risk" is not enough! 
The following question remains open: 1) 
whether, for medications that currently have unclear 
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pro-carcinogenic action (???), there are data that the 
incidence of melanoma is increased? And (2) why 
drugs with a proven carcinogenic effect are withdrawn 
without explanation at the moment what forms of 
cancer are found within their application [1], [2], [3], 
[4], [5], [6], [7]. The facts are the least disturbing. And 
such data surely exists! This indirectly speaks that 
pharmaceutical companies in all likelihood have 
databases for the frequency of a particular type of 
cancer that occurred within or after the application of a 
particular drug? However, such data should be 
formalised at the moment. Namely-that such facts (as 
shared by us) could hardly be confessed by 
companies that, for example, pay 370 million dollars 
to the US court and keep the direction of their 
domestic policy only for "inner consumption" or far 
from the media noise [16].  
The other contradictory issue, statement, or 
point of view should be the following: Is it possible for 
certain pharmaceutical companies to distribute 
products with carcinogenic substances, while at the 
same time the company/is in question offer/s a wide 
range of medications for the treatment of melanomas 
and other advanced cancers? Although conspiratorial, 
the answer is categorical: Yes! Companies that 
withdraw certain medications or for which there is 
evidence of association with cutaneous melanomas, 
at the same time are engaged in the treatment of the 
latter! And are among the top 10 pharmaceutical 
companies! One superficial analysis of the data shows 
that this is a reality. And it can be verified in all media. 
Interestingly, the case described is the 
second formalised by us regarding the relationship 
between irbesartan and melanoma. We presented a 
patient with a precursor melanocytic lesion, initially 
identified as a melanocytic nevus, which changes its 
size six times and progressed to melanoma, the latter 
occurring 1.5-2 years after systemic intake of 
irbesartan. A sporadic association may be available, 
but we think it is less likely. 
In conclusion, the probability, in the presence 
of precursor lesions, the intake of irbesartan to trigger 
their development towards melanoma, is completely 
real. This is confirmed by the presented by us (so far) 
two different patients with arterial hypertension, 
controlled with irbesartan, manufactured by various 
pharmaceutical companies. This indirectly speaks in 
favour of the notion that the primary substance, not 
possibly NDMA/NDEA contamination, is the basis for 
potentiation of carcinogenesis? The possible, but 
highly unlikely hypothesis that the melanoma 
development in adults is simply associated with the 
intake of angiotensin receptor blockers is not 
excluded. 
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